Fred R. Hirsch, MD, PhD, on Searching for Therapeutic Strategies for Patients With Lung Cancer and COVID-19 Infection

0 seconds of 0 secondsVolume 90%

00:00

Fred R. Hirsch, MD, PhD, on Searching for Therapeutic Strategies for Patients With Lung Cancer and COVID-19 Infection

IASLC 2020 World Conference on Lung Cancer in Singapore

Fred R. Hirsch, MD, PhD, of Mount Sinai Medical Center, invites his colleagues to enroll their patients in a large prospective study, for which he serves as Principal Investigator. The study is searching for solutions for treating patients with lung cancer who also have the coronavirus, because so many experience an aggressive course of infection.

Bruce E. Johnson, MD, on Evolving Challenges in Lung Cancer Drug Development

Bruce E. Johnson, MD, of Dana-Farber Cancer Institute, offers his expert perspective on single-arm drug approvals for targeted agents between 2016 and 2020, the need for biomarker testing, and the societal costs of drug development (Abstract PL04.03).

Lung Cancer

Immunotherapy

The ASCO Post Staff

Dean Fennell, FRCP, PhD, on Mesothelioma: Nivolumab vs Placebo in Relapsed Disease

Dean Fennell, FRCP, PhD, of the University of Leicester, discusses phase III results from the CONFIRM trial, which sought a standard immunotherapy treatment to improve overall survival for patients with mesothelioma who have relapsed after taking pemetrexed and cisplatin. Globally, the incidence of mesothelioma is on the rise; in the United Kingdom alone, it has gone up nearly 500% since the 1970s (Abstract PS01.11).

Lung Cancer

Immunotherapy

The ASCO Post Staff

Fred R. Hirsch, MD, PhD, on Lung Cancer: Survival and Tumor Mutation Burden

Fred R. Hirsch, MD, PhD, of Mount Sinai Medical Center, discusses Lung-MAP studies in which a higher tumor mutation burden determined by next-generation sequencing was linked to overall and progression-free survival across two immunotherapy trials, and was independent of PD-L1 status (Abstract OA01.04).

Lung Cancer

The ASCO Post Staff

Giorgio V. Scagliotti, MD, PhD, on Doubling the Lung Cancer Cure Rate by 2025: A Realistic Goal

Giorgio V. Scagliotti, MD, PhD, of the University of Torino, talks about why he believes that many more patients with lung cancer can be cured within the next 4 years, given decreases in mortality rates, widespread use of targeted treatments and immunotherapies, and earlier diagnoses as a result of systematic screening with low-dose CT (Abstract PL05.08).

Solid Tumors

Immunotherapy

The ASCO Post Staff

Prasad S. Adusumilli, MD, on Cell Therapy for Solid Tumors

Prasad S. Adusumilli, MD, of Memorial Sloan Kettering Cancer Center, discusses ongoing CAR T-cell therapy clinical trials for solid tumors, the key determinants of success for developing this treatment, and some study results to date (Abstract PL03.05).

Apr

Today In Oncology

Fred R. Hirsch, MD, PhD, on Searching for Therapeutic Strategies for Patients With Lung Cancer and COVID-19 Infection

Related Videos

Bruce E. Johnson, MD, on Evolving Challenges in Lung Cancer Drug Development

Dean Fennell, FRCP, PhD, on Mesothelioma: Nivolumab vs Placebo in Relapsed Disease

Fred R. Hirsch, MD, PhD, on Lung Cancer: Survival and Tumor Mutation Burden

Giorgio V. Scagliotti, MD, PhD, on Doubling the Lung Cancer Cure Rate by 2025: A Realistic Goal

Prasad S. Adusumilli, MD, on Cell Therapy for Solid Tumors

Most Pediatric Cancer Deaths Occur in Regions of Conflict

FDA Approves Bevacizumab Biosimilar

Ideal Apixaban Dose for Cancer-Associated VTE

Metastatic Castration-Resistant Prostate Cancer Immune-Modulating ADC Targeting CD46

Novel Strategy May Enhance Sensitivity of Monitoring Cancer in Blood Samples